logo

Company’s Banking Stock: Dissecting a -0.68% Quarterly Revenue Decline Amid Growth

SLGG

Halozyme Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $65.53 on 08/29/24, with the lowest value being $33.15 on 02/05/24.

52-week price history of HALO Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Halozyme Therapeutics Inc’s current trading price is -17.96% away from its 52-week high, while its distance from the 52-week low is 62.17%. The stock’s price range for this period has remained between $33.15 and $65.53. The Healthcare sector company’s shares managed to surpass a trading volume of around 2.67 million for the day, which was noticeably higher compared to the shares’ average daily volume of 1.65 million over the last three months.

Financial Performance and Market Capitalization

Halozyme Therapeutics Inc (HALO) has experienced a quarterly decline of -0.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.84B and boasts a workforce of 373 employees.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 54.11, with a change in price of -5.34. Similarly, Halozyme Therapeutics Inc recorded 1,556,270 in trading volume during the last 100 days, posting a change of -9.04%.

HALO Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HALO stands at 3.32. Similarly, the long-term debt-to-equity ratio is also 3.32.

HALO Stock Stochastic Average

As of today, the raw stochastic average of Halozyme Therapeutics Inc over the last 50 days is at 58.41%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 85.81%. Further, the company’s Stochastic %K and %D values for the last 20 days were 89.75% and 75.49%, respectively.

HALO Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded an increase of 12.45%. However, over the last six months, the performance has been weaker by 1.51%. The price of HALO increased 11.07% over the last 30 days. And in the last five days, it has surged by 12.45%.

Most Popular